+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cutaneous T-Cell Lymphoma(CTCL) - Epidemiology Forecast - 2032

  • PDF Icon

    Report

  • 150 Pages
  • September 2022
  • Region: Global
  • DelveInsight
  • ID: 4330603
This ‘Cutaneous T-cell Lymphoma - Epidemiology Forecast-2032' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2019-2032

Cutaneous T-cell Lymphoma Disease Understanding

Cutaneous T-cell Lymphoma Overview

Cutaneous T-cell lymphoma (CTCL) is a group of disorders characterized by abnormal accumulation of malignant T-cells in the skin potentially resulting in the development of rashes, plaques, and tumors. Furthermore, more than three out of every four skin lymphomas diagnosed are CTCLs and often appear as eczema-like skin rashes and can affect widespread parts of the body. Most CTCLs typically fall into the category of indolent (i.e. chronic) lymphomas - treatable, but not curable and usually not life-threatening.

Several types of cutaneous T-cell lymphoma exist. The most common type is mycosis fungoides. Sezary syndrome is a less common type that causes skin redness over the entire body. Some types of cutaneous T-cell lymphoma, such as mycosis fungoides, progress slowly and others are more aggressive.

Signs and symptoms of CTCL include formation of patches and lumps on skin, enlarged lymph nodes, hair loss, thickening of the skin on the palms of the hands and soles of the feet and rash-like skin redness over the entire body that is intensely itchy.

Different staging systems have been proposed for CTCLs. The most accepted and widely used system is the tumor-node-metastasis (TNM) system.

It includes the following stages:

  • Stage I (presence of red, scaly patches or plaques of skin, no involvement of the lymph nodes, blood, or additional organ systems)
  • Stage II (IIA: presence of red, scaly patches of skin, but no tumors, enlarged lymph nodes, but without the presence of cancer cells; IIB: tumors are present. Lymph nodes may be enlarged, but without the presence of cancer cells)
  • Stage III (nearly all of the skin is red and scaly. Lymph nodes may be enlarged, but without presence of cancer cells)
  • Stage IV (red, scaly skin and involvement of lymph nodes or additional organ systems (e.g., liver, lungs, spleen)).

Cutaneous T-cell Lymphoma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident population of CTCL, type-specific population of CTCL, subtype-specific population of CTCL, gender-specific population of CTCL, stage-specific population of CTCL, treatment eligible incident population in early and advanced stage in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the CTCL epidemiology in the 7MM

Country Wise- Cutaneous T-cell Lymphoma Epidemiology

  • The epidemiology segment also provides the CTCL epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The total incident population of CTCL in the 7MM comprised of 7,485 cases in 2021 and are projected to increase during the forecast period.
  • The total incident population of CTCL in the United States is 3,415 in 2021.
  • The United States contributed to the largest incident population of CTCL, accounting for ~ 46% of the 7MM in 2021.
  • Among the EU5 countries, Germany accounted for the highest number of CTCL cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
  • In Japan, the total incident population of CTCL was 1,316 in 2021 and is anticipated to rise during the forecast period.
  • The major types of CTCL include Mycosis Fungoides (MF), CD30+ lymphoproliferative disorder (LPD), Sezary Syndrome (SS), and others. In 2021, the incident population of MF, LPD, SS, and other types in the United States were 2,049, 683, 171, and 512 cases.
  • In 2021, males and females accounted for 1,814 and 1,602 cases respectively in the United States.
  • In the United States, there were 2,254 early stage, and 1,161 late stage cases in 2021.

Scope of the Report

  • The report covers the descriptive overview of CTCL, explaining its causes, signs and symptoms, pathogenesis and diagnosis.
  • Comprehensive insight has been provided into the CTCL epidemiology and treatment.
  • The report provides insight about the historical and forecasted patient pool of CTCL in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • A detailed review of CTCL epidemiology forecast is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding epidemiological trends.

Report Highlights

  • In the coming years, CTCL market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, increase in incidence population.
  • As per the analysis the major types of CTCL include Mycosis Fungoides (MF), CD30+ lymphoproliferative disorder (LPD), Sezary Syndrome (SS), and others.
  • The report also encompasses other major segments, i.e., total incident population of CTCL, type-specific population of CTCL, subtype-specific population of CTCL, gender-specific population of CTCL, stage-specific population of CTCL, treatment eligible incident population in early and advanced stage.

CTCL Report Insights

  • Patient Population
  • Eleven Years Forecast
  • 7MM Coverage
  • CTCL Epidemiology Segmentation

Key Questions

  • What is the disease risk, burden and unmet needs of CTCL?
  • What is the historical CTCL patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of CTCL at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CTCL?
  • Out of the above-mentioned countries, which country would have the highest incident population of CTCL during the study period (2019-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the CTCL.
  • To understand the future market competition in the CTCL market and Insightful review of the unmet needs.
  • Quantify patient populations in the global CTCL market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the best opportunities for CTCL in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • The CTCL Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.

Table of Contents

1. Key Insights2. Report Introduction3. Executive Summary4. Epidemiology Methodology
5. CTCL Market Overview at a Glance
5.1. Patient share (%) of CTCL in 2021
5.2. Patient share (%) of CTCL in 2032
6. Disease Background and Overview
6.1. Introduction
6.2. Classification
6.3. Symptoms
6.4. Etiopathogenesis
6.5. Genomic Landscape of SS/MF
6.6. Biomarkers
6.7. Diagnosis
6.8. Staging and Assessment
7. Epidemiology and Patient Population of CTCL in the 7MM
7.1. Key Findings
7.1.1. United States
7.1.2. EU5
7.1.3. Japan
8.2. Total Incident Population of CTCL in the 7MM
8.3. The United States
8.3.1. Total Incident Population of CTCL in the United States
8.3.2. Type-specific Cases of CTCL in the United States
8.3.3. Subtype-specific Cases of MF in the United States
8.3.4. Gender-specific CTCL cases in the United States
8.3.5. Stage-specific Cases of CTCL in the United States
8.3.6. Treatment eligible incident population in Early and Advanced Stage in the United States
8.4. The EU5
8.4.1. Total Incident Population of CTCL in the EU5
8.4.2. Type-specific cases of CTCL in the EU5
8.4.3. Subtype-specific cases of MF in the EU5
8.4.4. Gender-specific CTCL cases in the EU5
8.4.5. Stage-specific Cases of CTCL in the EU5
8.4.6. Treatment eligible incident population in Early and Advanced Stage in the EU5
8.5. Japan
8.5.1. Total Incident Population of CTCL in Japan
8.5.2. Type-specific Cases of CTCL in Japan
8.5.3. Subtype-specific Cases of MF in Japan
8.5.4. Gender-specific CTCL cases in Japan
8.5.5. Stage-specific Cases of CTCL in Japan
8.5.6. Treatment eligible incident population in Early and Advanced Stage in Japan
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. Publisher Capabilities11. Disclaimer12. About the Publisher
List of Tables
Table 1: Summary of CTCL, and Epidemiology (2019-2032)
Table 2: Lymphomatoid Papulosis: Histologic Subtypes and Differential Diagnosis
Table 3: Characteristic Clinical and Immunophenotypic Features of Various Types of CTCL
Table 4: TNMB Classification and Staging of Mycosis Fungoides and Sezary Syndrome
Table 5: Clinical Staging of Mycosis Fungoides and Sezary Syndrome
Table 6: Total Incident Population of CTCL in the 7MM (2019-2032)
Table 7: Total Incident Population of CTCL in the US (2019-2032)
Table 8: Type-specific cases of CTCL in the US (2019-2032)
Table 9: Subtype-specific cases of CTCL in the US (2019-2032)
Table 10: Gender-specific CTCL cases in the US (2019-2032)
Table 11: Stage-specific cases of CTCL in the US (2019-2032)
Table 12: Treatment eligible incident population in Early and Advanced Stage in the US (2019-2032)
Table 13: Total Incident Population of CTCL in the EU5 (2019-2032)
Table 14: Type-specific cases of CTCL in Germany (2019-2032)
Table 15: Type-specific cases of CTCL in France (2019-2032)
Table 16: Type-specific cases of CTCL in Italy (2019-2032)
Table 17: Type-specific cases of CTCL in Spain (2019-2032)
Table 18: Type-specific cases of CTCL in the UK (2019-2032)
Table 19: Type-specific cases of CTCL in the EU5 (2019-2032)
Table 20: Subtype-specific cases of MF in Germany (2019-2032)
Table 21: Subtype-specific cases of MF in France (2019-2032)
Table 22: Subtype-specific cases of MF in Italy (2019-2032)
Table 23: Subtype-specific cases of MF in Spain (2019-2032)
Table 24: Subtype-specific cases of MF in the UK (2019-2032)
Table 25: Subtype-specific cases of MF in the EU5 (2019-2032)
Table 26: Gender-specific CTCL cases in Germany (2019-2032)
Table 27: Gender-specific CTCL cases in France (2019-2032)
Table 28: Gender-specific CTCL cases in Italy (2019-2032)
Table 29: Gender-specific CTCL cases in Spain (2019-2032)
Table 30: Gender-specific CTCL cases in the UK (2019-2032)
Table 31: Gender-specific CTCL cases in the EU5 (2019-2032)
Table 32: Stage-specific cases of CTCL in Germany (2019-2032)
Table 33: Stage-specific cases of CTCL in France (2019-2032)
Table 34: Stage-specific cases of CTCL in Italy (2019-2032)
Table 35: Stage-specific cases of CTCL in Spain (2019-2032)
Table 36: Stage-specific cases of CTCL in the UK (2019-2032)
Table 37: Stage-specific cases of CTCL in the EU5 (2019-2032)
Table 38: Treatment eligible incident population in Early and Advanced Stage in Germany (2019-2032)
Table 39: Treatment eligible incident population in Early and Advanced Stage in France (2019-2032)
Table 40: Treatment eligible incident population in Early and Advanced Stage in Italy (2019-2032)
Table 41: Treatment eligible incident population in Early and Advanced Stage in Spain (2019-2032)
Table 42: Treatment eligible incident population in Early and Advanced Stage in the UK (2019-2032)
Table 43: Treatment eligible incident population in Early and Advanced Stage in the EU5 (2019-2032)
Table 44: Total Incident Population of CTCL in Japan (2019-2032)
Table 45: Type-specific cases of CTCL in Japan (2019-2032)
Table 46: Subtype-specific cases of CTCL in Japan (2019-2032)
Table 47: Gender-specific CTCL cases in Japan (2019-2032)
Table 48: Stage-specific cases of CTCL in Japan (2019-2032)
Table 49: Treatment eligible incident population in Early and Advanced Stage in Japan (2019-2032)
List of Figures
Figure 1: Total Incident Population of CTCL in the 7MM (2019-2032)
Figure 2: Total Incident Population of CTCL in the US (2019-2032)
Figure 3: Type-specific cases of CTCL in the US (2019-2032)
Figure 4: Subtype-specific cases of MF in the US (2019-2032)
Figure 5: Gender-specific CTCL cases in the US (2019-2032)
Figure 6: Stage-specific cases of CTCL in the US (2019-2032)
Figure 7: Treatment eligible incident population in Early and Advanced Stage in the US (2019-2032)
Figure 8: Total Incident Population of CTCL in the EU5 (2019-2032)
Figure 9: Type-specific cases of CTCL in the EU5 (2019-2032)
Figure 10: Subtype-specific cases of MF in the EU5 (2019-2032)
Figure 11: Gender-specific CTCL cases in the EU5 (2019-2032)
Figure 12: Stage-specific cases of CTCL in the EU5 (2019-2032)
Figure 13: Treatment eligible incident population in Early and Advanced Stage in the EU5 (2019-2032)
Figure 14: Total Incident Population of CTCL in Japan (2019-2032)
Figure 15: Type-specific cases of CTCL in Japan (2019-2032)
Figure 16: Subtype-specific cases of MF in Japan (2019-2032)
Figure 17: Gender-specific CTCL cases in Japan (2019-2032)
Figure 18: Stage-specific Cases of CTCL in Japan (2019-2032)
Figure 19: Treatment eligible incident population in Early and Advanced Stage in Japan (2019-2032)